New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease

Dapagliflozin is cost-effective for chronic kidney disease compared with standard of care, in the UK, Germany, and Spain, despite the fact that the drug has high acquisition costs, finds a new analysis.

Related Keywords

United States ,Spain ,Germany ,United Kingdom ,Spanish ,American ,German ,Phil Mcewan ,Los Angeles ,Annika Khine ,Eugene Lin ,Kline ,American Society Of Nephrology ,Drug Administration ,University Of Southern California ,Adverse Outcomes ,American Society ,Clinical Journal ,Southern California ,Medical Center ,Incremental Cost Effectiveness ,New England Journal ,Medscape Medical ,Ends Up Costing More ,Healthier Patients ,Inflation Reduction Act ,Chronic Renal Failure ,Hronic Kidney Failure ,Hronic Kidney Disease Ckd ,Chronic Kidney Disease ,Kd ,Renal Failure ,Enal Insufficiency ,Idney Insufficiency ,Kidney Failure ,Renal Disease ,Kidney Disease ,Kidney Disorder ,Renal Disorder ,Ephropathy ,Kidneys ,End Stage Renal Disease Esrd ,End Stage Renal Disease ,Srd ,Transplantation Kidney ,Renal Transplantation ,Ransplantation Renal ,The ,